NewsBenzingaEli Lilly's Once-Daily Oral Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg On Weight Loss, A1C At 52 Weeks In Type 2 Diabetes Indirect Comparison Presented At EASD Milan Eli Lilly's Once-Daily Oral Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg On Weight Loss, A1C At 52 Weeks In Type 2 Diabetes Indirect Comparison Presented At EASD Milan Benzinga 2026.09.29 07:28 (GMT+0) Open on Benzinga Other news Eli Lilly’s Next Weight-Loss Drug Helped Patients Lose Up to 54 Pounds. Why the FDA’s New Warning Didn’t Hurt LLY Stock. Galaxy Digital shares fall 8% Friday, weekly decline exceeds 20% Lean Groups Certify Claude-Assisted Riemann Proof Here are the top AI agents that can live in your text messages Coatue Management Bets on SK hynix Stock as Demand for HBM Chips Accelerates Target, Biotech Lead 5 Stocks Showing Strength In Brutal Market
Eli Lilly’s Next Weight-Loss Drug Helped Patients Lose Up to 54 Pounds. Why the FDA’s New Warning Didn’t Hurt LLY Stock.